Current status of the management of patients with endocrine-sensitive tumors. II. Carcinoma of the prostate, endometrium, thyroid, kidney and miscellaneous tumors.
D002369:Castration; D004717:Endometrium; D004967:Estrogens / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000139:chemically induced / Q000209:etiology*; D008297:Male; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011372:Progestins / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013964:Thyroid Neoplasms / Q000139:chemically induced / Q000209:etiology*; D001749:Urinary Bladder Neoplasms / Q000209:etiology; D014594:Uterine Neoplasms / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology*
D004967:Estrogens; D011372:Progestins